{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-24-000150","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.109209+00:00","generated_at":"2026-06-03T05:33:27.019315+00:00","sec_items":["1.01","8.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease","bullets":["Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.","Consulting covers Facebook and Twitter management; shares are unregistered restricted securities.","Amended sublease with BST Partners (controlled by CEO David Koos) to reimburse shared expenses in addition to $5k/month base rent.","Subtenant also required to pay shared expenses retroactive to January 1, 2024, per amendment.","Both transactions involve related party: David Koos is CEO and also controls BST Partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-24-000150","json":"https://secwatch.observer/filing/0001607062-24-000150.json","markdown":"https://secwatch.observer/filing/0001607062-24-000150.md","text":"https://secwatch.observer/filing/0001607062-24-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706224000150/0001607062-24-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706224000150/rgbp042924form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:33:27.019315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}